(Circulation. 2001;103:1396.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
From Micromet AG (D.Z., A.M., T.N., P.A.B.); 1 Medzinische Klinik (D.Z., A.S., F.-J.N.), Pathologisches Institut (T.R.); Abteilung für Gefäßchirurgie (R.B.), Technische Universität München; and the Institut für Immunologie (C.A.K.), Ludwig-Maximilian-Universität, München, Germany.
Correspondence to Dr Dietlind Zohlnhöfer, 1 Medizinische Klinik und Deutsches Herzzentrum, Technische Universität München, Lazarettstr. 36, D-80636 München, Germany. E-mail d_zohlnhoefer{at}yahoo.com
BackgroundRestenosis due to neointima formation is the major limitation of stent-supported balloon angioplasty. Despite abundant animal data, molecular mechanisms of neointima formation have been investigated on only a limited basis in patients. This study sought to establish a method for profiling gene expression in human in-stent neointima and to identify differentially expressed genes that may serve as novel therapeutic targets.
Methods and ResultsWe retrieved tissue specimens from patients with symptomatic in-stent restenosis using a novel helix cutter atherectomy device. cDNA samples prepared from neointima (n=10) and, as a control, from the media of normal arteries (n=14) were amplified using a novel polymerase chain reaction protocol and hybridized to cDNA arrays. Immunohistochemistry characterized the atherectomy material as neointima. cDNA arrays readily identified differentially expressed genes. Some of the differentially expressed genes complied with expected gene expression patterns of neointima, including downregulation of desmin and upregulation of thrombospondin-1, cyclooxygenase-1, and the 70-kDa heat shock protein B. Additionally, we discovered previously unknown gene expression patterns, such as downregulation of mammary-derived growth inhibitor and upregulation of FK506-binding protein 12 (FKBP12). Upregulation of FKBP12 was confirmed at the protein level in neointimal smooth muscle cells.
ConclusionsGene expression patterns of human neointima retrieved by helix-cutter atherectomy can be reliably analyzed by cDNA array technology. This technique can identify therapeutic targets in patients, as exemplified by the findings regarding FKBP12. FKBP12 is the receptor for Rapamycin (sirolimus), which in animal models reduced neointima formation. Our study thus yields a rationale for the use of Rapamycin to prevent restenosis in patients.
Key Words: genes restenosis stents molecular biology polymerase chain reaction
This article has been cited by other articles:
![]() |
Y. Diao, S. Guthrie, S.-L. Xia, X. Ouyang, L. Zhang, J. Xue, P. Lee, M. Grant, E. Scott, and M. S. Segal Long-Term Engraftment of Bone Marrow-Derived Cells in the Intimal Hyperplasia Lesion of Autologous Vein Grafts Am. J. Pathol., March 1, 2008; 172(3): 839 - 848. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gick, N. Jander, H.-P. Bestehorn, R.-P. Kienzle, M. Ferenc, K. Werner, T. Comberg, K. Peitz, D. Zohlnhofer, V. Bassignana, et al. Randomized Evaluation of the Effects of Filter-Based Distal Protection on Myocardial Perfusion and Infarct Size After Primary Percutaneous Catheter Intervention in Myocardial Infarction With and Without ST-Segment Elevation Circulation, September 6, 2005; 112(10): 1462 - 1469. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fukuda, M. Sata, K. Tanaka, and R. Nagai Potent Inhibitory Effect of Sirolimus on Circulating Vascular Progenitor Cells Circulation, February 22, 2005; 111(7): 926 - 931. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Toutouzas, A. Colombo, and C. Stefanadis Inflammation and restenosis after percutaneous coronary interventions Eur. Heart J., October 1, 2004; 25(19): 1679 - 1687. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J Carter, M. Aggarwal, G. A Kopia, F. Tio, P. S Tsao, R. Kolata, A. C Yeung, G. Llanos, J. Dooley, and R. Falotico Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model Cardiovasc Res, September 1, 2004; 63(4): 617 - 624. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Zohlnhofer, T. G. Nuhrenberg, F.-J. Neumann, T. Richter, A. E. May, R. Schmidt, K. Denker, M. A. Clauss, A. Schomig, and P. A. Baeuerle Rapamycin Effects Transcriptional Programs in Smooth Muscle Cells Controlling Proliferative and Inflammatory Properties Mol. Pharmacol., April 1, 2004; 65(4): 880 - 889. [Abstract] [Full Text] |
||||
![]() |
E. Bell, X. Cao, J. A. Moibi, S. R. Greene, R. Young, M. Trucco, Z. Gao, F. M. Matschinsky, S. Deng, J. F. Markman, et al. Rapamycin Has a Deleterious Effect on MIN-6 Cells and Rat and Human Islets Diabetes, November 1, 2003; 52(11): 2731 - 2739. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. G. Nabel Cardiovascular Disease N. Engl. J. Med., July 3, 2003; 349(1): 60 - 72. [Full Text] [PDF] |
||||
![]() |
O. I. Stenina, I. Krukovets, K. Wang, Z. Zhou, F. Forudi, M. S. Penn, E. J. Topol, and E. F. Plow Increased Expression of Thrombospondin-1 in Vessel Wall of Diabetic Zucker Rat Circulation, July 1, 2003; 107(25): 3209 - 3215. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Kim, K. A. Skelding, E. G. Nabel, and R. D. Simari What can cardiovascular gene transfer learn from genomics: and vice versa? Physiol Genomics, December 3, 2002; 11(3): 179 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. J. Zhang, M. Goddard, C. Shanahan, L. Shapiro, and M. Bennett Differential Gene Expression in Vascular Smooth Muscle Cells in Primary Atherosclerosis and In Stent Stenosis in Humans Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 2030 - 2036. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Lymn, M. K. Patel, G. F. Clunn, S. J. Rao, K. L. Gallagher, and A. D. Hughes Thrombospondin-1 differentially induces chemotaxis and DNA synthesis of human venous smooth muscle cells at the receptor-binding level J. Cell Sci., November 15, 2002; 115(22): 4353 - 4360. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Duda, B. Pusich, G. Richter, P. Landwehr, V. L. Oliva, A. Tielbeek, B. Wiesinger, J. B. Hak, H. Tielemans, G. Ziemer, et al. Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease: Six-Month Results Circulation, September 17, 2002; 106(12): 1505 - 1509. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ichii, H. Koyama, S. Tanaka, A. Shioi, Y. Okuno, S. Otani, and Y. Nishizawa Thrombospondin-1 Mediates Smooth Muscle Cell Proliferation Induced by Interaction With Human Platelets Arterioscler. Thromb. Vasc. Biol., August 1, 2002; 22(8): 1286 - 1292. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Haller Percutaneous coronary interventions in patients with renal failure: overcoming in-stent restenosis? Nephrol. Dial. Transplant., May 1, 2002; 17(5): 701 - 703. [Full Text] [PDF] |
||||
![]() |
P W Serruys, E Regar, and A J Carter Rapamycin eluting stent: the onset of a new era in interventional cardiology Heart, April 1, 2002; 87(4): 305 - 307. [Full Text] [PDF] |
||||
![]() |
P.A Henriksen and Y Kotelevtsev Application of gene expression profiling to cardiovascular disease Cardiovasc Res, April 1, 2002; 54(1): 16 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Lowe, L. M. Khachigian, J. Sun, S. O. Marx, H.-J. Chen, A. R. Marks, L. E. Rabbani, and M. Poon Coating Stents With Antirestenotic Drugs: The Blunderbuss or the Magic Bullet? Response Circulation, January 29, 2002; 105 (4): e29 - e29. [Full Text] [PDF] |
||||
![]() |
H. C. Lowe, S. N. Oesterle, and L. M. Khachigian Coronary in-stent restenosis: Current status and future strategies J. Am. Coll. Cardiol., January 16, 2002; 39(2): 183 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Sousa, M. A. Costa, A. C. Abizaid, B. J. Rensing, A. S. Abizaid, L. F. Tanajura, K. Kozuma, G. Van Langenhove, A. G.M.R. Sousa, R. Falotico, et al. Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up Circulation, October 23, 2001; 104(17): 2007 - 2011. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Lowe, R. G. Fahmy, M. M. Kavurma, A. Baker, C. N. Chesterman, and L. M. Khachigian Catalytic Oligodeoxynucleotides Define a Key Regulatory Role for Early Growth Response Factor-1 in the Porcine Model of Coronary In-Stent Restenosis Circ. Res., October 12, 2001; 89(8): 670 - 677. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |